ω-Substituted alkyl carboxylic acids as antidiabetic and lipid-lowering agents

被引:10
|
作者
Meyer, K
Voss, E
Neidlein, R
Kühnle, HF
Pill, J
机构
[1] Boehringer Mannheim GmbH, Therapeut Res, D-6800 Mannheim, Germany
[2] Univ Heidelberg, Inst Pharmazeut Chem, D-6900 Heidelberg, Germany
关键词
omega-substituted alkyl carboxylic acids; insulin sensitizer; lipid lowering;
D O I
10.1016/S0223-5234(99)80029-4
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
In screening experiments certain omega-substituted alkyl carboxylic acids were found to produce an increase in insulin-stimulated C-14-acetate incorporation into triglycerides, which may indicate an improvement in the action of insulin. Antidiabetic and lipid-lowering properties in genetically diabetic ob/ob mice demonstrated the in vivo relevance of the insulin-potentiating effects seen in vitro. The chemical structures of the w-substituted alkyl carboxylic acids with insulin-potentiating effects correspond to the general formula ring-spacer-COOH. A close structure-activity relationship was observed. The most potent compound in ob/ob mice was 3e, which normalized blood glucose as well as hyperinsulinaemia and lowered serum triglycerides and cholesterol by 52% and 37%, respectively. On the basis of these results, omega-substituted alkyl carboxylic acids are interesting as a new class of oral antidiabetic agents with insulin-sensitizing and lipid-lowering activity. (C) Elsevier, Paris.
引用
收藏
页码:775 / 787
页数:13
相关论文
共 50 条
  • [31] Pharmacogenomics of lipid-lowering agents: the impact on efficacy and safety
    Shatnawi, Aymen
    Kamran, Zourayz
    Al-Share, Qusai
    PERSONALIZED MEDICINE, 2023, 20 (01) : 65 - 85
  • [32] New lipid-lowering agents acting on LDL receptors
    Scharnagl, H
    März, W
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2005, 5 (03) : 233 - 242
  • [33] Lipid-lowering agents and new onset diabetes mellitus
    Athyros, Vasilios G.
    Tziomalos, Konstantinos
    Karagiannis, Asterios
    Mikhailidis, Dimitri P.
    EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (12) : 1965 - 1970
  • [34] Statins in atherosclerosis: Lipid-lowering agents with antioxidant capabilities
    Rosenson, RS
    ATHEROSCLEROSIS, 2004, 173 (01) : 1 - 12
  • [35] Pharmacogenetics of Lipid-Lowering Agents: Precision or Indecision Medicine?
    Alfonsi, Jeffrey E.
    Hegele, Robert A.
    Gryn, Steven E.
    CURRENT ATHEROSCLEROSIS REPORTS, 2016, 18 (05)
  • [36] Drug-drug interactions involving combinations of antipsychotic agents with antidiabetic, lipid-lowering, and weight loss drugs
    Buzea, Catalin Adrian
    Manu, Peter
    Dima, Lorena
    Correll, Christoph U. U.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2022, 18 (11) : 729 - 744
  • [37] Differential effects of lipid-lowering agents on human cholinesterases
    Darvesh, S
    Martin, E
    Walsh, R
    Rockwood, K
    CLINICAL BIOCHEMISTRY, 2004, 37 (01) : 42 - 49
  • [38] Myotoxicity of Lipid-Lowering Agents in a Teenager With MELAS Mutation
    Tay, Stacey K. H.
    DiMauro, Salvatore
    Pang, Aileen Y. W.
    Lai, Poh-San
    Yap, Hui-Kim
    PEDIATRIC NEUROLOGY, 2008, 39 (06) : 426 - 428
  • [39] Hypercholesterolemia, lipid-lowering agents, and the risk for brain infarction
    Amarenco, P
    NEUROLOGY, 2001, 57 (05) : S35 - S44
  • [40] Pharmacogenetics of Lipid-Lowering Agents: Precision or Indecision Medicine?
    Jeffrey E. Alfonsi
    Robert A. Hegele
    Steven E. Gryn
    Current Atherosclerosis Reports, 2016, 18